Pharmaceuticals

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.

A new partnership embeds programmatic ads into electronic health records, promising hyper-targeted marketing but raising questions about clinical disruption.

Ski champion Lindsey Vonn leverages her Olympic comeback to partner with biopharma firm Invivyd, aiming to educate Americans on antibody-based disease prevention.

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

A new global consortium aims to break the antibiotic R&D logjam, using open science and AI to combat the growing superbug crisis threatening millions.

Simulations Plus reveals its new AI-driven ecosystem, aiming to solve pharma's biggest R&D hurdles with a focus on regulatory trust and integration.

A major benefits group is pushing Congress to pass key healthcare reforms that could lower drug prices and hospital bills before a critical Jan. 30 deadline.

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

A new therapy for a rare blood cancer gets a major boost from the FDA, offering hope for thousands of myelofibrosis patients with limited options.

A new journal issue reveals how venture capital, advanced clinical insights, and patient-centered drug design are creating a new era in heart failure care.

With healthcare costs surging, Benepass's new funding will expand its platform to give employers greater control and employees more choice in benefits.

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

After a $16.5M funding round, the smart-shipping innovator hires a top finance exec to scale its attack on the $35B problem of spoiled medicine.

A new, self-administered RNA therapy for hereditary angioedema gains EU approval, promising fewer attacks and greater freedom for thousands of patients.

BioAge Labs is developing an oral drug for diabetic macular edema, a breakthrough that could end the need for frequent, invasive eye injections for millions.

A new partnership promises up to 22% savings for employers by integrating deep pharmacy expertise, tackling one of healthcare's most complex challenges.

A new AI-driven platform from CAS aims to democratize complex IP research, making high-stakes patent analysis accessible to entire organizations.

Novavax lands a major partnership with Pfizer for its Matrix-M adjuvant, a deal that provides a crucial financial boost and validates its pivot to a tech provider.

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.